143 related articles for article (PubMed ID: 25871383)
1. PI3K pan-inhibition impairs more efficiently proliferation and survival of T-cell acute lymphoblastic leukemia cell lines when compared to isoform-selective PI3K inhibitors.
Lonetti A; Cappellini A; Spartà AM; Chiarini F; Buontempo F; Evangelisti C; Evangelisti C; Orsini E; McCubrey JA; Martelli AM
Oncotarget; 2015 Apr; 6(12):10399-414. PubMed ID: 25871383
[TBL] [Abstract][Full Text] [Related]
2. Anti-leukaemic activity of the TYK2 selective inhibitor NDI-031301 in T-cell acute lymphoblastic leukaemia.
Akahane K; Li Z; Etchin J; Berezovskaya A; Gjini E; Masse CE; Miao W; Rocnik J; Kapeller R; Greenwood JR; Tiv H; Sanda T; Weinstock DM; Look AT
Br J Haematol; 2017 Apr; 177(2):271-282. PubMed ID: 28295194
[TBL] [Abstract][Full Text] [Related]
3. Development of small-molecule inhibitors that target PI3Kβ.
Yu Y; Gu D; Cai L; Yang H; Sheng R
Drug Discov Today; 2024 Jan; 29(1):103854. PubMed ID: 38070704
[TBL] [Abstract][Full Text] [Related]
4. Class (I) Phosphoinositide 3-Kinases in the Tumor Microenvironment.
Gyori D; Chessa T; Hawkins PT; Stephens LR
Cancers (Basel); 2017 Mar; 9(3):. PubMed ID: 28273837
[TBL] [Abstract][Full Text] [Related]
5. Novel PIKfyve/Tubulin Dual-target Inhibitor as a Promising Therapeutic Strategy for B-cell Acute Lymphoblastic Leukemia.
Lu Z; Lai Q; Li ZF; Zhong MY; Jiang YL; Feng LY; Zha J; Yao JW; Li Y; Deng XM; Xu B
Curr Med Sci; 2024 Apr; 44(2):298-308. PubMed ID: 38619682
[TBL] [Abstract][Full Text] [Related]
6. Targeting the PI5P4K Lipid Kinase Family in Cancer Using Covalent Inhibitors.
Sivakumaren SC; Shim H; Zhang T; Ferguson FM; Lundquist MR; Browne CM; Seo HS; Paddock MN; Manz TD; Jiang B; Hao MF; Krishnan P; Wang DG; Yang TJ; Kwiatkowski NP; Ficarro SB; Cunningham JM; Marto JA; Dhe-Paganon S; Cantley LC; Gray NS
Cell Chem Biol; 2020 May; 27(5):525-537.e6. PubMed ID: 32130941
[TBL] [Abstract][Full Text] [Related]
7. The Therapeutic Potential for PI3K Inhibitors in Autoimmune Rheumatic Diseases.
Banham-Hall E; Clatworthy MR; Okkenhaug K
Open Rheumatol J; 2012; 6():245-58. PubMed ID: 23028409
[TBL] [Abstract][Full Text] [Related]
8. Isoform-selective targeting of PI3K: time to consider new opportunities?
Cirillo D; Diceglie M; Nazaré M
Trends Pharmacol Sci; 2023 Sep; 44(9):601-621. PubMed ID: 37438206
[TBL] [Abstract][Full Text] [Related]
9. A high affinity pan-PI3K binding module supports selective targeted protein degradation of PI3Kα.
Jauslin WT; Schild M; Schaefer T; Borsari C; Orbegozo C; Bissegger L; Zhanybekova S; Ritz D; Schmidt A; Wymann M; Gillingham D
Chem Sci; 2024 Jan; 15(2):683-691. PubMed ID: 38179525
[TBL] [Abstract][Full Text] [Related]
10. Correction: A high affinity pan-PI3K binding module supports selective targeted protein degradation of PI3Kα.
Jauslin WT; Schild M; Schaefer T; Borsari C; Orbegozo C; Bissegger L; Zhanybekova S; Ritz D; Schmidt A; Wymann M; Gillingham D
Chem Sci; 2024 Jan; 15(4):1520. PubMed ID: 38274068
[TBL] [Abstract][Full Text] [Related]
11. The phosphoinositide-3-kinase (PI3K)-delta and gamma inhibitor, IPI-145 (Duvelisib), overcomes signals from the PI3K/AKT/S6 pathway and promotes apoptosis in CLL.
Balakrishnan K; Peluso M; Fu M; Rosin NY; Burger JA; Wierda WG; Keating MJ; Faia K; O'Brien S; Kutok JL; Gandhi V
Leukemia; 2015 Sep; 29(9):1811-22. PubMed ID: 25917267
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of phosphatidylinositol-3 kinase inhibitors with diverse isoform selectivity profiles for inhibiting the survival of chronic lymphocytic leukemia cells.
Göckeritz E; Kerwien S; Baumann M; Wigger M; Vondey V; Neumann L; Landwehr T; Wendtner CM; Klein C; Liu N; Hallek M; Frenzel LP; Krause G
Int J Cancer; 2015 Nov; 137(9):2234-42. PubMed ID: 25912635
[TBL] [Abstract][Full Text] [Related]
13. How I treat T-cell acute lymphoblastic leukemia in adults.
Litzow MR; Ferrando AA
Blood; 2015 Aug; 126(7):833-41. PubMed ID: 25966987
[TBL] [Abstract][Full Text] [Related]
14. [Molecular genetics of acute lymphoblastic leukemia].
Tamai H; Inokuchi K
Rinsho Ketsueki; 2015 Mar; 56(3):253-60. PubMed ID: 25876777
[TBL] [Abstract][Full Text] [Related]
15. MEK Inhibitor PD-0325901 Overcomes Resistance to PI3K/mTOR Inhibitor PF-5212384 and Potentiates Antitumor Effects in Human Head and Neck Squamous Cell Carcinoma.
Mohan S; Vander Broek R; Shah S; Eytan DF; Pierce ML; Carlson SG; Coupar JF; Zhang J; Cheng H; Chen Z; Van Waes C
Clin Cancer Res; 2015 Sep; 21(17):3946-56. PubMed ID: 25977343
[TBL] [Abstract][Full Text] [Related]
16. Leukemia stem cells in T-ALL require active Hif1α and Wnt signaling.
Giambra V; Jenkins CE; Lam SH; Hoofd C; Belmonte M; Wang X; Gusscott S; Gracias D; Weng AP
Blood; 2015 Jun; 125(25):3917-27. PubMed ID: 25934477
[TBL] [Abstract][Full Text] [Related]
17. Identification of differential PI3K pathway target dependencies in T-cell acute lymphoblastic leukemia through a large cancer cell panel screen.
Lynch JT; McEwen R; Crafter C; McDermott U; Garnett MJ; Barry ST; Davies BR
Oncotarget; 2016 Apr; 7(16):22128-39. PubMed ID: 26989080
[TBL] [Abstract][Full Text] [Related]
18. CXCR4 Is Required for Leukemia-Initiating Cell Activity in T Cell Acute Lymphoblastic Leukemia.
Passaro D; Irigoyen M; Catherinet C; Gachet S; Da Costa De Jesus C; Lasgi C; Tran Quang C; Ghysdael J
Cancer Cell; 2015 Jun; 27(6):769-79. PubMed ID: 26058076
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of autophagy enhances the anticancer activity of bortezomib in B-cell acute lymphoblastic leukemia cells.
Wang Z; Zhu S; Zhang G; Liu S
Am J Cancer Res; 2015; 5(2):639-50. PubMed ID: 25973303
[TBL] [Abstract][Full Text] [Related]
20. Future of Therapy in Acute Lymphoblastic Leukemia (ALL)--Potential Role of Immune-Based Therapies.
Kebriaei P; Poon ML
Curr Hematol Malig Rep; 2015 Jun; 10(2):76-85. PubMed ID: 25899862
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
